These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19173813)

  • 21. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
    Haim N; Ben-Shahar M; Epelbaum R
    Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
    Biagi JJ; Herbert KE; Smith C; Abdi E; Leahy M; Falkson C; Wolf M; Januszewicz H; Seymour JF; Richards K; Matthews JP; Dale B; Prince HM
    Leuk Lymphoma; 2005 Feb; 46(2):197-206. PubMed ID: 15621802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
    Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
    Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
    Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
    Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma].
    Hou Y; Wang HQ; Fu K; Liu XM; Zhang HL; Qian ZZ; Qiu LH; Li W; Zhou SY; Li LF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):306-10. PubMed ID: 22781046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
    Abali H; Oyan B; Koc Y; Kars A; Barista I; Uner A; Turker A; Demirkazik F; Tekin F; Tekuzman G; Kansu E
    Am J Clin Oncol; 2005 Jun; 28(3):264-9. PubMed ID: 15923799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
    Aurer I; Duraković N; Radman I; Nemet D; Zupancić-Salek S; Kovacević-Metelko J; Bogdanić V; Sertić D; Mrsić M; Mikulić M; Labar B
    Croat Med J; 2002 Oct; 43(5):550-4. PubMed ID: 12402394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
    Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
    Lazar AD; Shpilberg O; Shaklai M; Bairey O
    Isr Med Assoc J; 2009 Jan; 11(1):16-22. PubMed ID: 19344007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
    Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA
    J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
    Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
    Rinsho Ketsueki; 1994 Jul; 35(7):635-41. PubMed ID: 8065017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.